Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL)

Summary: Treatment options for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) after failure of platinum-based therapy are limited. In this phase 2 trial, 40 patients with RM-NPC who failed platinum-based chemotherapy receive toripalimab plus anlotinib regimen. The objective...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Yuchen Zhang, Qihua Zou, Baitian Zhao, Ning Su, Zhihua Li, Xicheng Wang, Panpan Liu, Xiaopeng Tian, Xiaojie Fang, Jun Cai, Lirong Li, Yingxian Liu, Yi Xia, Qingqing Cai
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2024-12-01
Serie:	Cell Reports Medicine
Ämnen:	nasopharyngeal carcinoma recurrent or metastatic toripalimab anlotinib circulating tumor DNA clinical trial
Länkar:	http://www.sciencedirect.com/science/article/pii/S2666379124006049
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!